Top Biotech Stocks To Buy For 2018

Xbiotech’s potential upside vs. downside

Xbiotech (NASDAQ:XBIT) has presented the abstract of its European Phase III trial of Xilonix to treat patients with metastatic colorectal cancer (mCRC) refractory to standard treatment at the ESMO GI (European Society for Medical Oncology) 2016, early July. The abstract has shown a 76% relative increase in clinical response rate (CRR), associated with a 2.7-fold increase in median overall survival (11.5 vs. 4.2 months responders vs. non-responders), an increase in Lean Body Mass (LBM) and an improved Quality of Life (QoL) with little safety concerns, all surrogate parameters for anti-cancer activity and prolonged survival – see ESMO Press release and my previous SA article.

This abstract came under scrutiny by the discussant, an executive member of the ESMO, at the same conference, questioning whether those results “is any benefit in translating this trial into practice.” – press release ESMO .

Others, like Adam Feuerstein, right away played on the above criticism, taking down Xbiotech’s results – see here, here. In my opinion I still do not have an explanation on how Adam Feuerstein was able to tweet about the OS data before those were presented, other than receiving it from an insider. His tweet was made one day before the scheduled presentation that the Congress – see agenda to compare. In addition, neither on the presentation slide nor on the press release of the discussant issued by ESMO was a declaration of conflict of interest. It goes without saying that the discussant- obviously together with another colleague and executive director of ESMO – are biased towards Xbiotech and Xilonix. Both were prominent figures in clinical trials of Regorafenib and Lonsurf (trifluridine/tipiracil), currently the only two drugs approved for last-line treatment in mCRC refractory to standard therapy. In my opinion such a bias should have been declared. Furthermore, the discussant held several positions with big pharmaceuticals, including Regorafenib’s Bayer AG (OTCPK:BAYZF, OTCPK:BAYRY)- see CME information from Medscape.

Top Biotech Stocks To Buy For 2018: Callidus Software, Inc.(CALD)

Advisors’ Opinion:

  • [By Lisa Levin]

    In trading on Monday, technology shares fell 0.14 percent. Meanwhile, top losers in the sector included Sequans Communications SA ADR (NYSE: SQNS), down 8 percent, and Callidus Software Inc. (NASDAQ: CALD), down 6 percent.

Top Biotech Stocks To Buy For 2018: GenMark Diagnostics, Inc.(GNMK)

Advisors’ Opinion:

  • [By Lisa Levin]

    GenMark Diagnostics, Inc (NASDAQ: GNMK) shares shot up 20 percent to $10.54. Cowen & Co. upgraded GenMark Diagnostics from Market Perform to Outperform.

Top Biotech Stocks To Buy For 2018: New Century Bancorp Inc.(NC)

Advisors’ Opinion:

  • [By Lisa Levin]

    Shares of NACCO Industries, Inc. (NYSE: NC) got a boost, shooting up 11 percent to $73.85. NACCO Industries disclosed that its subsidiary Hamilton Beach Brands has filed to trade as an independent company. The company announced the retirement of its CEO following Hamilton Beach Brands spin off.

Leave a Reply

Your email address will not be published. Required fields are marked *